Alnylam Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Alnylam Pharmaceuticals Il CEO è Yvonne Greenstreet, nominato in Jan2022, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 8.90M, composta da 11% di stipendio e 89% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.039% delle azioni della società, per un valore di MX$ 253.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 9 anni.

Informazioni chiave

Yvonne Greenstreet

Amministratore delegato

US$8.9m

Compenso totale

Percentuale dello stipendio del CEO	11.0%
Mandato del CEO	2.8yrs
Proprietà del CEO	0.04%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yvonne Greenstreet rispetto agli utili di Alnylam Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$332m
Jun 30 2024	n/a	n/a	-US$73m
Mar 31 2024	n/a	n/a	-US$332m
Dec 31 2023	US$9m	US$976k	-US$440m
Sep 30 2023	n/a	n/a	-US$510m
Jun 30 2023	n/a	n/a	-US$1b
Mar 31 2023	n/a	n/a	-US$1b
Dec 31 2022	US$5m	US$850k	-US$1b
Sep 30 2022	n/a	n/a	-US$1b
Jun 30 2022	n/a	n/a	-US$981m
Mar 31 2022	n/a	n/a	-US$893m
Dec 31 2021	US$9m	US$619k	-US$853m
Sep 30 2021	n/a	n/a	-US$838m
Jun 30 2021	n/a	n/a	-US$887m
Mar 31 2021	n/a	n/a	-US$876m
Dec 31 2020	US$3m	US$622k	-US$858m
Sep 30 2020	n/a	n/a	-US$891m
Jun 30 2020	n/a	n/a	-US$846m
Mar 31 2020	n/a	n/a	-US$886m
Dec 31 2019	US$3m	US$571k	-US$886m
Sep 30 2019	n/a	n/a	-US$821m
Jun 30 2019	n/a	n/a	-US$858m
Mar 31 2019	n/a	n/a	-US$802m
Dec 31 2018	US$3m	US$540k	-US$761m
Sep 30 2018	n/a	n/a	-US$692m
Jun 30 2018	n/a	n/a	-US$570m
Mar 31 2018	n/a	n/a	-US$525m
Dec 31 2017	US$985k	US$504k	-US$491m

Compensazione vs Mercato: La retribuzione totale di Yvonne ($USD 8.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 5.71M ).

Compensazione vs guadagni: La retribuzione di Yvonne è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Yvonne Greenstreet (61 yo)

2.8yrs

Mandato

US$8,895,670

Compensazione

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yvonne Greenstreet	CEO & Director	2.8yrs	US$8.90m	0.039% MX$ 253.0m
Jeffrey Poulton	CFO & Executive VP	5.3yrs	US$3.22m	0.016% MX$ 107.1m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	1.1yrs	US$3.32m	0.018% MX$ 117.7m
Pushkal Garg	Chief Medical Officer	10.1yrs	US$3.23m	0.0090% MX$ 58.8m
Tolga Tanguler	Executive VP & Chief Commercial Officer	3.8yrs	US$2.87m	0.0054% MX$ 34.9m
Timothy Maines	Chief Technical Operations & Quality Officer	1.8yrs	Nessun dato	Nessun dato
Kevin Fitzgerald	Senior VP	5.5yrs	Nessun dato	0.010% MX$ 67.8m
Piyush Sharma	Chief Ethics & Compliance Officer	2.2yrs	Nessun dato	Nessun dato
Robert Hesslein	Chief Legal Officer & Corporate Secretary	less than a year	Nessun dato	Nessun dato
Christine Lindenboom	Chief Corporate Communications Officer	no data	Nessun dato	Nessun dato
Evan Lippman	Chief Corporate Development & Strategy Officer	2.2yrs	Nessun dato	Nessun dato
Kelley Boucher	Chief Human Resource Officer	5.5yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di ALNY * è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yvonne Greenstreet	CEO & Director	3.1yrs	US$8.90m	0.039% MX$ 253.0m
Akshay Vaishnaw	Chief Innovation Officer & Member of the Scientific Advisory Board	no data	US$3.32m	0.018% MX$ 117.7m
Muthiah Manoharan	Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board	9.1yrs	Nessun dato	Nessun dato
Peter Kellogg	Independent Director	1.7yrs	US$658.72k	0% MX$ 0
Paul Schimmel	Member of the Scientific Advisory Board	no data	US$516.04k	Nessun dato
David E. Pyott	Independent Director	8.9yrs	US$477.21k	0.022% MX$ 141.6m
Phillip Sharp	Co-Founder	22.4yrs	US$502.21k	0.21% MX$ 1.3b
Amy W. Schulman	Independent Chair of the Board & Lead Independent Director	10.3yrs	US$531.36k	0.0065% MX$ 42.6m
Markus Stoffel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
David Bartel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Dennis Ausiello	Member of the Scientific Advisory Board & Independent Director	12.6yrs	US$477.21k	0.0028% MX$ 18.4m
Colleen Reitan	Independent Director	6.4yrs	US$489.15k	0% MX$ 0

9.0yrs

Durata media

69.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALNY * sono considerati esperti (durata media dell'incarico 9 anni).

Alnylam Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CEO & Director recently sold Mex$35m worth of stock

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

CEO & Director recently sold Mex$18m worth of stock

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

President recently sold Mex$13m worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023)

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$2.21 loss in 2Q 2023)

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director recently sold Mex$35m worth of stock

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

CEO & Director recently sold Mex$18m worth of stock

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

President recently sold Mex$13m worth of stock

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

CEO & Director recently sold Mex$27m worth of stock

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$1.15 loss per share (vs US$1.61 loss in 2Q 2021)

Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022

No longer forecast to breakeven

Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering Rna to the Central Nervous System and Other Extrahepatic Tissues

Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis of Exploratory Cardiac Endpoints in the HELIOS-A Phase 3 Study of Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces That Health Canada Has Issued A Notice of Compliance (Noc) Authorizing Oxlumo™ (Lumasiran) Injection for Subcutaneous Use for the Treatment

First quarter 2022 earnings released: US$2.00 loss per share (vs US$1.71 loss in 1Q 2021)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Alnylam Pharmaceuticals, Inc. Announces Retirement of Steven Paul from Board of Directors

Alnylam Pharmaceuticals, Inc. Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat